Harvard Bioscience Subsidiary Multi Channel Systems Launches Beta Cell Screening System for Diabetes Research, Entering New Segment of Electrophysiology Market
The Beta Cell-System leverages MCS’s multi electrode array (MEA) technology to take non-invasive measurements from intact islets of Langerhans. It opens a new route to support the development of new drugs for the treatment of type 2 diabetes mellitus, as well as to elucidate beta cell pathophysiology e.g. during the progression of diabetes. Glucose-dependent electrical oscillatory activity in beta cells within islets of Langerhans is important for understanding their physiology and pathophysiology.
“We believe that our Beta Cell-System will help researchers make strides in finding new diabetes treatments and gain further insights into this disease by providing advantages to support disease progression studies and new drug development,” said
Key advantages of the Beta Cell-System include:
- Non-invasive method enables long-term in vitro research
- Simpler experimental handling and higher throughput than conventional methods compatible with the needs of academic and industrial laboratories
- Easier and faster to use than conventional, invasive methods such as patch-clamp and recording with intracellular electrodes
- Measurements from intact islets
- Suitable for diabetes research including drug development
Focused on the needs of academic and industrial laboratories, the Beta Cell-System is available in two configurations to support either long-term studies within an incubator or fast, medium throughput screening applications.
The electrophysiology division of
Director, Finance and Investor Relations
Tel: 508 893 8999
Tel: 212 825 3210
Source: Harvard Bioscience, Inc.